Vergent Bioscience
A clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by significantly improving the visibility of tumors.
Launch date
Employees
Market cap
-
Enterprise valuation
$86—129m (Dealroom.co estimates Oct 2022.)
Minneapolis Minnesota (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| $8.7m | Series A | |
| N/A | $1.0m | Early VC | |
* | $21.5m | Series B | |
| Total Funding | $31.2m | ||
Related Content
Recent News about Vergent Bioscience
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.